Aragen Bioscience, Inc. and Transposagen Biopharmaceuticals, Inc. have filed three petitions for IPR of Kyowa Hakko Kirin Co., Ltd.’s patents: IPR2017-01262 on U.S. Patent 7,425,446; IPR2017-01252 on U.S. Patent 6,946,292; and IPR2017-01254 on U.S. Patent 8,067,232. According to the petitions, the challenged claims are “directed to an isolated mammalian host cell producing antibodies that function more effectively because they do not have a particular fructose sugar on their Fc regions.” (See petitions at 1.)
These three patents are at issue in a district court litigation involving the same parties as those in the IPRs, 3-16-cv-05993, pending in the District Court for the Northern District of California. According to the complaint, filed in October, 2016, Aragen and Transposagen offer cell lines that infringe the patents.
These petitions and selected other documents on IPRs concerning biologic products are posted on our IPR Tracker page.
